

## Etanercept

Cat. No.:	HY-108847
CAS No.:	185243-69-0
Target:	TNF Receptor; Bacterial
Pathway:	Apoptosis; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF- $\alpha$ and TNF- $\beta$ to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis <sup>[1][2][3]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	Fas								
<b>In Vivo</b>	<p>Etanercept (10 mg/kg; s.c.; every 3 days for 3 weeks) significantly decreases the mean arthritis scores and radiological score [4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Six-week-old male Lewis rats (adjuvant-induced arthritis (AIA) model)<sup>[4]</sup></td></tr><tr><td>Dosage:</td><td>10 mg/kg</td></tr><tr><td>Administration:</td><td>S.c.; every 3 days for 3 weeks</td></tr><tr><td>Result:</td><td>Significantly decreased the mean arthritis scores; Significant decreased in radiological score at the end of the treatment period.</td></tr></table>	Animal Model:	Six-week-old male Lewis rats (adjuvant-induced arthritis (AIA) model) <sup>[4]</sup>	Dosage:	10 mg/kg	Administration:	S.c.; every 3 days for 3 weeks	Result:	Significantly decreased the mean arthritis scores; Significant decreased in radiological score at the end of the treatment period.
Animal Model:	Six-week-old male Lewis rats (adjuvant-induced arthritis (AIA) model) <sup>[4]</sup>								
Dosage:	10 mg/kg								
Administration:	S.c.; every 3 days for 3 weeks								
Result:	Significantly decreased the mean arthritis scores; Significant decreased in radiological score at the end of the treatment period.								

### CUSTOMER VALIDATION

- Genes Dis. 20 June 2022.
- Clin Exp Immunol. 2023 Jul 4;uxad071.
- World J Stem Cells. 2022; 14(11): 798-814.
- SSRN. 2023 Nov 28.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

- 
- [1]. Goffe B, et al. Etanercept: An overview. *J Am Acad Dermatol*. 2003;49(2 Suppl):S105-S111.
- [2]. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. *Clin Ther*. 1999;21(1):75-2.
- [3]. Totoson P, et al. Etanercept improves endothelial function via pleiotropic effects in rat adjuvant-induced arthritis. *Rheumatology (Oxford)*. 2016;55(7):1308-1317.
- [4]. Haraoui B, et al. Etanercept in the treatment of rheumatoid arthritis. *Ther Clin Risk Manag*. 2007;3(1):99-105.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA